Experienced in Succinic Semialdehyde Dehydrogenase Deficiency

Asako Horino

Tokyo, JP 
Experienced in Succinic Semialdehyde Dehydrogenase Deficiency
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Asako Horino practices in Tokyo, Japan. Ms. Horino is rated as an Experienced expert by MediFind in the treatment of Succinic Semialdehyde Dehydrogenase Deficiency. Her top areas of expertise are West Syndrome, Encephalitis, Epilepsy, Anti-NMDA Receptor Encephalitis, and Pacemaker Implantation.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Succinic Semialdehyde Dehydrogenase Deficiency.

Gender
Female

Locations

Tokyo, 1568506, Japan
Other Locations
Osaka, Japan
Setagaya, 1568506, Japan
Shizuoka, 4208688, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
Enrollment Status: Completed
Publish Date: September 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
Enrollment Status: Completed
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

26 Total Publications

Total callosotomy ameliorates epileptic activity and improves cognitive function in a patient with Miller-Dieker syndrome.
Total callosotomy ameliorates epileptic activity and improves cognitive function in a patient with Miller-Dieker syndrome.
Journal: Epilepsy & behavior reports
Published: February 09, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Horino's expertise for a condition
ConditionClose
      View All 26 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile